FREE ELECTRONIC LIBRARY - Dissertations, online materials

Pages:   || 2 |

«Galderma and ZELTIQ Announce U.S. Collaboration in Aesthetics Collaboration will deliver healthcare professionals and consumers enhanced value and ...»

-- [ Page 1 ] --

Galderma and ZELTIQ Announce U.S. Collaboration in Aesthetics

Collaboration will deliver healthcare professionals and consumers

enhanced value and access to leading facial and body aesthetic innovations

FORT WORTH, Texas & PLEASANTON, California, December 8, 2015 – Galderma, a global leader

in skin health, and ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused

on developing its proprietary controlled-cooling technology platform, today announced a new

collaboration across the companies’ innovative aesthetic brands and offerings. Effective immediately, the creation of this nationwide collaboration between two of the fastest-growing companies in the aesthetic space will provide healthcare professionals and consumers with greater access to a robust range of technologically-advanced and scientifically-proven beauty solutions for facial rejuvenation and non-invasive fat reduction.

Galderma markets leading aesthetic brands including Dysport® (abobotulinumtoxinA), for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines); the newly launched Restylane® Silk, the first product specifically designed to treat the lips and lines around the mouth; Restylane® Lyft, the first and only FDA-approved filler indicated to provide fullness to the midface area (cheeks) and correct and smooth the nasolabial folds ("smile lines"); and Sculptra® Aesthetic, a long-acting dermal filler, which stimulates natural collagen production, helping to increase the elasticity of the skin and smooth out deep wrinkles and folds.

ZELTIQ brings the world’s number one non-invasive fat reduction procedure, CoolSculpting®, to the new collaboration. The breakthrough procedure safely and effectively reduces unwanted fat without surgery or downtime using a patented cooling technology. Millions of CoolSculpting treatments have been performed worldwide.

In addition, the two companies will create connections between the Galderma portfolio of aesthetic brands and ZELTIQ’s CoolSculpting procedure for healthcare professionals and consumers through their respective industry-leading loyalty programs: ASPIRE Galderma Rewards loyalty program (www.aspirerewards.com) and Crystal Rewards (www.coolsculpting.com).

“The collaboration between Galderma and ZELTIQ is extremely exciting and will provide value to my practice and patients,” said Grant Stevens, MD, FACS, a board-certified plastic surgeon in California. “For many years, I have used and trusted Galderma aesthetic brands and ZELTIQ’s CoolSculpting. I am pleased this collaboration will result in greater access to these valuable products, as well as added benefits for my practice and patients through the ASPIRE Galderma Rewards and Crystal Rewards loyalty programs.” “Galderma’s aesthetic brands and ZELTIQ’s CoolSculpting are some of the most popular aesthetic procedures performed in my practice,” said Jody Comstock, MD, a board-certified dermatologist in Arizona. “This collaboration is great news for healthcare specialists and MP-MIX-00118 consumers alike and demonstrates Galderma’s and ZELTIQ’s commitment to the aesthetics market.” “At Galderma, we are focused on advancing skin health and driving category innovation for natural looking results. Through this uniquely-designed collaboration with ZELTIQ, we are bringing together leading facial aesthetic technology and non-invasive fat reduction to better serve and provide long-term value to our healthcare specialists, as well as increase awareness among consumers,” said Kelly Huang, PhD, Vice President and General Manager, Aesthetic and Corrective Business Unit, Galderma, U.S.

“ZELTIQ has revolutionized non-invasive fat reduction, as demonstrated by both physicians and consumers embracing CoolSculpting and making it the market leader. We are thrilled to collaborate with Galderma, a company that also has strong relationships in and a deep commitment to the aesthetic category,” said Mark Foley, President and Chief Executive Officer of ZELTIQ. “Our shared goal in this collaboration is to combine innovation and technology with relationships to create an extraordinary offering for healthcare professionals and consumers.” Galderma and ZELTIQ plan to initiate a joint educational effort, as well as market growth strategies to benefit both healthcare providers and consumers.

About Galderma Dating back to 1961, Galderma is now present in 80 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime.

Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

Strategic brands in the U.S. include Epiduo® Gel, Oracea® Capsules, Clobex® Spray, Differin® Gel, Mirvaso® Gel, MetroGel® Gel, Soolantra® Cream, Vectical® Cream, Tri-Luma® Cream, Cetaphil®, Benzac® Acne Solutions, Excipial® Skin Solutions, Restylane®, Restylane® Silk, Restylane® Lyft, Dysport® (abobotulinumtoxinA) and Sculptra® Aesthetic. For more information, please visit www.galderma.com and www.galdermausa.com.

About ZELTIQ ZELTIQ® is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® system, is designed to selectively reduce unwanted fat that may not respond to diet or exercise. The CoolSculpting procedure is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process MP-MIX-00118 known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.

All trademarks are the property of their respective owners.

For Galderma, contact:

Virginie Naigeon Director of Corporate Communications, Galderma U.S.

virginie.naigeon@galderma.com Ronna Waldman MMC +1-212-485-6907 rwaldman@mahercomm.com

For ZELTIQ, contact:


Adrienne Kemp Gold PR +1-949-922-0801


Patrick F. Williams ZELTIQ, Senior Vice President and CFO +1-925-474-2500 Nick Laudico The Ruth Group +1-646-536-7030 MP-MIX-00118 Dysport Important Safety Information Dysport is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age.

Distant Spread of Toxin Effect Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.

These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.


• Dysport is contraindicated in patients with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

• This product may contain trace amounts of cow’s milk protein. Patients known to be allergic to cow’s milk protein should not be treated with Dysport.

• Dysport is contraindicated for use in patients with infection at the proposed injection site(s).


The potency Units of Dysport are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.


Facial Anatomy in the Treatment of Glabellar Lines

• Caution should be exercised when administering Dysport to patients with surgical alterations to the facial anatomy, excessive weakness or atrophy in the target muscle(s), marked facial asymmetry, inflammation at the injection site(s), ptosis, excessive dermatochalasis, deep MP-MIX-00118 dermal scarring, thick sebaceous skin or the inability to substantially lessen glabellar lines by physically spreading them apart.

• Do not exceed the recommended dosage and frequency of administration of Dysport. In clinical trials, subjects who received a higher dose of Dysport had an increased incidence of eyelid ptosis.

Pre-existing Neuromuscular Disorders

• Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin.

• Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of Dysport.

Human Albumin

• This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.

• A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote. No cases of transmission of viral diseases or CJD have ever been reported for albumin.

Intradermal Immune Reaction

• The possibility of an immune reaction when injected intradermally is unknown.

• The safety of Dysport for the treatment of hyperhidrosis has not been established.


• In clinical studies, the most frequently reported adverse events (≥2%) were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis and nausea.


• Patients treated concomitantly with botulinum toxins and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should be observed closely because the effect of the botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of Dysport may potentiate systemic anticholinergic effects such as blurred vision.


• The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

• Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of Dysport.


• Dysport is not recommended for use in children or pregnant women.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information including Medication Guide.

Restylane Family Important Safety Information Indications: The Restylane family of products includes Restylane®, Restylane-L®, Restylane® Silk, Restylane® Lyft with Lidocaine, and Perlane®. Restylane, Restylane-L, Restylane Lyft with Lidocaine, and Perlane are indicated for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Restylane and Restylane-L are indicated for mid-to-deep dermal implantation. Perlane and Restylane Lyft with Lidocaine are indicated for implantation into the deep dermis to superficial subcutis. Restylane Silk is indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. Restylane Lyft with Lidocaine is also indicated for cheek augmentation and for the correction of age-related midface contour deficiencies in patients over the age of 21. Restylane and Restylane-L are also indicated for submucosal implantation for lip augmentation in patients over the age of 21.

Products in the Restylane family contain traces of gram-positive bacterial protein and are contraindicated for patients with allergies to such material or in patients with severe allergies that have required in-hospital treatment. These products should not be used by patients with bleeding disorders or by pregnant or breastfeeding women. Restylane and Restylane-L for lip enhancement and Restylane Silk should not be used by people under 22 years. Restylane-L, Restylane Silk and Restylane Lyft with Lidocaine should not be used by anyone with a known allergy to lidocaine. Products should not be injected anywhere except the dermis, superficial subcutis (Perlane and Restylane Lyft with Lidocaine only), or lip submucosa (Restylane, Restylane-L, and Restylane Silk only).

Pages:   || 2 |

Similar works:

«ISSUES IN THE MEASUREMENT AND REPORTING OF WORK HEALTH AND SAFETY PERFORMANCE: A REVIEW November 2013 This report was co-funded by Safe Work Australia, Safety Institute of Australia and CPA Australia.Authors: Dr Sharron O’Neill International Governance and Performance (IGAP) Research Centre Macquarie University Professor Nonna Martinov-Bennie International Governance and Performance (IGAP) Research Centre Macquarie University Ms Angela Cheung International Governance and Performance (IGAP)...»

«9 Appendices 9.1 References AHC (2013). Zero tolerance to fraud in the Solomon Islands Australian aid program. Australian High Commission. Available: http://www. solomonislands.embassy.gov.au/honi/1304301.html. Anonymous (2011). Solomon Islands Highlighted in ‘Aid Fraud’ Report. Solomon Times Online. Anonymous (2013). Solomon Islands tsunami deaths confirmed. The Guardian, 7 February 2013. ANU (2013). 2013 SIG RAMSI People’s Survey Report. Canberra: The Australian National University and...»

«Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Nurofen for Children Sachets 100 mg/5 ml Oral Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ibuprofen 100 mg per 5 ml sachet. Contains 1.625 ml of maltitol liquid per 5 ml sachet. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral suspension. An off-white orange-flavoured syrup-like suspension. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Reduction of...»

«Consumer Medicine Information VALACICLOVIR RBX Valaciclovir 500 mg Tablets What is in this leaflet This leaflet answers some common questions about VALACICLOVIR RBX (valaciclovir). It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. This leaflet was written on the date at the end of this leaflet. More recent information may be available. The latest Consumer Medicine Information is available from https://www.medsafe.govt.nz/ and...»

«Venice 2012, Fourth International Symposium on Energy from Biomass and Waste Nutrient recovery from digestates: techniques and end-products V. LEBUF*, F. ACCOE*, C. VANEECKHAUTE**, E. MEERS**, E. MICHELS**, G. GHEKIERE*** * Flemish Coordination Centre for Manure Processing, Brugge, Belgium ** Faculty of Bioscience Engineering, Ghent University, Belgium *** Inagro, Rumbeke-Beitem, Belgium SUMMARY In nitrate vulnerable zones application of animal manure to land is limited. Digestate from...»

«NHS Dorset Clinical Commissioning Group Procedure for the management of Serious Incidents Supporting people in Dorset to lead healthier lives 1 PREFACE This procedural document outlines the processes to be adopted to ensure the thorough investigation of Serious Incidents reported to, and by, NHS Dorset CCG. All managers and staff (at all levels) are responsible for ensuring that they are viewing and working to the current version of this procedural document. If this document is printed in hard...»

«EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL Brussels, SANCO G (2013)2615272 SUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 14 JUNE 2013 (Section Animal Health & Welfare) Chair: A. Laddomada, A.E. Fuessel. 26 Member States were present. Cyprus was absent and represented by Greece. Croatia attended the meeting as an observer. A representative from the European Food Safety Authority (EFSA) was present during the presentation of item...»

«Priors Field Surgery A self help Guide to Minor Illness and Minor Injuries This booklet is provided to help you deal with minor illnesses yourself. It aims to explain some minor illnesses and injuries, suggest some simple remedies, and offer guidance about when you might need medical help. What do you mean, “a minor illness”? It doesn’t feel minor! A minor illness usually means one that will get better by itself, without causing any lasting harm, It doesn’t mean it feels minor it may...»

«Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end of the leaflet to establish if there have been any changes. If you have any doubts or queries about your medication, please contact your doctor or pharmacist. PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ULTRAVIST® 150 ULTRAVIST® 240 ULTRAVIST® 300 ULTRAVIST® 370 Iopromide Read all of this...»

«Aus dem Exzellenzcluster NeuroCure der Medizinischen Fakultät Charité – Universitätsmedizin Berlin Dissertation Regulation of Neurotransmitter Release by Essential Vesicular Proteins zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.) eingereicht im Fachbereich Biologie, Chemie, Pharmazie der Freien Universität Berlin vorgelegt von Johannes Zimmermann aus Hannover im März 2015 angefertigt im Zeitraum von Februar 2010 bis März 2015 im Labor von Prof....»

«Recommendation from the Scientific Committee on Occupational Exposure Limits for carbon tetrachloride SCOEL/SUM/31 June 2009 European Commission Employment, Social Affairs and Inclusion Recommendation from the Scientific Committee on Occupational Exposure Limits for carbon tetrachloride Table of Contents 1. Occurrence/use 2. Health Significance 2.1 Toxicokinetics Biological monitoring 2.2 Acute toxicity 2.2.1 Human data 2.2.2 Animal data 2.3 Irritation and corrosivity 2.3.1 Human data 2.3.2...»

«chapter 1 Colombia: After a Decade of Health System Reform María-Luisa Escobar, Ursula Giedion, Antonio Giuffrida, and Amanda L. Glassman Background and Context Colombia is a middle-income country with an estimated 2005 population of 43 million (Departamento Administrativo Nacional de Estadística/National Administrative Statistics Department, 2007). Over the past three decades, the Colombian population has experienced the demographic and epidemiological changes that characterize societies in...»

<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.